TGen and Affymetrix Partner to Use GeneChip(R) DNA Analysis Products in Major Collaborative Programs
Genotyping Technology that Leverages an Innovative Whole-Genome SNP Assay Is Available to Commercial and Academic Research Partners and Future Collaborators
Affymetrix, Inc. and the Translational genomics Research Institute (TGen) announced that they have entered into a non-exclusive agreement under which TGen will offer genotyping services to their collaborators and NIH funded core facility programs using Affymetrix GeneChip(R) brand DNA analysis technology.
TGen currently runs gene expression core facility programs on the Affymetrix platform for The National Institutes of Mental Health and the National Institutes of Neurological Disease and Stroke. As part of this agreement, these programs have been expanded to run the Affymetrix DNA analysis technologies. Affymetrix and TGen also agreed to a framework under which they will collaborate on future projects.
"Affymetrix Mapping 10K Array is a powerful tool for linkage analysis and is available today," said Dietrich Stephan, Ph.D., Director of TGen's Neurogenomics Program. "We recently completed a complete linkage study and reproduced the disease causing gene in just five days using the 10K. Affymetrix' cutting edge technology helped realize our vision of rapidly translating genomic discovery."
"TGen's geneticists, scientific team and one of the world's fastest super computers dedicated to the study of genetics combined with the Affymetrix SNP platform will help scientists accelerate research of complex diseases and we are thrilled to be a part of that," said Affymetrix' Chief Commercial Officer Trevor J. Nicholls, Ph.D. "The flexibility and affordability of the Mapping 10K will allow TGen to provide both large research institutions and individual researchers with the most powerful genotyping technology available today."
The Mapping 10K Array meets the growing customer demand for powerful SNP genotyping solutions in basic research, clinical research and development, drug discovery, and pharmacogenomics. The Mapping 10K Array brings whole genome SNP analysis to the bench top by combining an innovative, scalable assay with a proven information platform -- one primer, one array, 10,000 SNPs. The Mapping 10K delivers the most markers and highest resolution available in a single experiment, making it easier to pinpoint genomic regions linked to disease. Applications include genetic linkage studies of inherited disease in families, cancer genetics, and population genetics.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

How skin cells protect themselves against stress - Cell biologists have developed a new method for measuring how mechanical forces in cells are processed

Who am I? How cells find their identity
Discovery of the adherence mechanism of red algae to the rock
Plastics chemical retards growth, function of adult reproductive cells
Biotest AG: First time Revenue and EBIT contribution by Biotherapeutics Segment - Continuing difficult Plasma Protein Product Environment
Novasep to sell its Bahamian plant
Alligator Bioscience enters into research and option agreement with BioInvent to jointly develop Antibody-based therapeutics

'Big Data' used to identify new cancer driver genes
Newly discovered plant enzyme could lead to more efficient ethanol production from cellulose
Affimed Therapeutics AG expands clinical development team
Merck announces 2016 recipients of € 1 Million grant for Multiple Sclerosis Innovation - Four research grants awarded out of 260 proposals from 45 countries
